Genetic disease testing

Learning that you are expecting a baby is one of life's most joyous moments—but it can also be a source of concern when you learn that your pregnancy is considered a high-risk one. Women with heightened pregnancy risks routinely undergo genetic disease testing to rule out chromosomal disorders including Down Syndrome. As an alternative to invasive procedures such as amniocentesis, which carry a small risk of loss of the fetus, Eurofins Biomnis offers non-invasive genetic screening test during pregnancy, accurately detecting and identifying anomalies. The test involves a simple maternal blood sample, and offers over 99% accuracy. By opting for this genetic disease testing option, abnormalities can be screened early.

Although most expectant parents are aware of risks for fetal genetic defects, and wonder whether disorders such as Edwards'Syndrome can be detected, many people are unaware that genetic disease testing during pregnancy needs not be invasive. Thanks to groundbreaking efforts from researchers, effective and safe non-invasive testing methods are now readily available. Reliable and rapid, the test can be obtained starting in only the tenth week of pregnancy. It simultaneously detects risks for trisomies 13, 18 and 21—offering peace of mind from earlier on. Explore the website to learn more about why non-invasive genetic disease testing during pregnancy may be the right option for you.

When it comes to prenatal testing for trisomy, many people assume that genetic disorder screening during pregnancy necessarily entails traditional, potentially risky procedures such as amniocentesis. However, risk-free options are now available. The testing kit developed by Eurofins Biomnis is remarkably simple to administer. It can be prescribed by your regular healthcare provider, and you can have the blood test taken at your physician's office or at aEurofins Biomnis partner laboratory. With results of the blood test available in around 7 working days, NIPT byEurofins Biomis is a risk-free form ofnon-invasive genetic disorder screening during pregnancy. It has been found to reduce unnecessary invasive sampling by up to 95%.